Atopic dermatitis is a chronic skin disease with a heterogeneous and multifactorial pathogenesis theta is widespread in the population. For its treatment the effective regimens have been developed with both systemic and tropical drugs. The choice of therapeutic strategy for a pregnant woman depends on many factors: psychosocial, economic, the severity of disease, the influence of chosen therapeutic methods on pregnancy and the unborn child, etc. Taking this many factors into account it is difficult to choose the optimal method of therapy and achieve complete control over the disease. Since the course of atopic dermatitis during pregnancy is unpredictable it is important to assess the woman’s condition throughout the entire period of gestation and to adjust treatment accordingly. The prescribing systemic therapy in pregnant patients with a severe disease that cannot be corrected with topical agents can be considered when determining the therapeutic tactics. However, the use of many systemic drugs for atopic dermatitis therapy is limited or completely contraindicated. The use of topical medications in pregnant women with atopic dermatitis is preferred. In this case, the use of topical corticosteroids is becoming the treatment of choice. Among topical corticosteroids for the treatment of pregnant women, preference should be given to non-fluorinated drugs (prednisolone and methylprednisolone) that are metabolized in the placenta by the enzyme 11-b-hydroxysteroid dehydrogenase. Fluorinated steroids (betamethasone and dexamethasone) are metabolized at a much lower rate; fluticasone should not be used at all during pregnancy since it crosses the placental barrier unchanged.